gamma-Aminobutyric acid

Wayne State University enrolled Michigan's first patient in a Phase I/II trial testing stem cell-derived gabanergic interneurons to reduce epileptic seizures. The six-hour procedure uses robotic and stereotactic techniques, depositing cells secreting GABA in the hippocampus. The trial aims to assess safety and seizure frequency reduction, with 40 patients to be followed for 15 years post-transplant.

Olfactory dysfunction, prevalent in aging and Alzheimer's disease (AD), is linked to cognitive decline. AD, characterized by amyloid beta and tau protein accumulation, shows early olfactory impairment. Research highlights the role of inhibitory interneurons in olfactory areas, suggesting their dysfunction contributes to olfactory and cognitive deficits in aging and AD.

Diamyd Medical announced a positive FDA meeting, aligning on key elements for an accelerated approval pathway for Diamyd® (rhGAD65/alum), potentially allowing it to reach the market over a year earlier.

KDS2010, a novel MAO-B inhibitor, targets astrocytic GABA to stimulate metabolism and energy expenditure without affecting appetite. A Phase 2 trial for obesity is ongoing in South Korea, with U.S. cohort to be added in 2025. KDS2010 showed favorable safety and tolerability in Phase 1 trials.

Scilex Bio reports progress on obesity treatment KDS2010, with a Phase 2 trial enrolling 75 patients in South Korea, planning U.S. expansion in 2025. Phase 1 trials demonstrated favorable safety, tolerability, and pharmacokinetics for once-daily dosing. KDS2010, a reversible MAO-B inhibitor, stimulates metabolism without affecting appetite, potentially offering advantages over current treatments.

KDS2010, a novel MAO-B inhibitor, targets astrocytic GABA to stimulate metabolism and energy expenditure without affecting appetite. Ongoing Phase 2 obesity trials in South Korea will expand to the U.S. in 2025. Preclinical results show KDS2010 reduces obesity in mice by reducing tonic inhibition in the LHA.

A clinical trial of 4-phenylbutyrate (PBA) shows significant reduction in seizure activity among children with genetic mutations causing severe epilepsy. Some children who failed multiple anti-seizure drugs have become seizure-free. The research is supported by nonprofit patient advocacy organizations, SLC6A1 Connect and Cure GABA-A, founded by mothers of children with genetic epilepsy. The trial is conducted at Vanderbilt University Medical Center, Weill Cornell Medical Center, Children's Hospital Colorado, and the University of Texas Southwestern Medical Center.

Scilex Holding Company forms joint venture, Scilex Bio, with IPMC and Bio Open Innovation Consortium to develop and commercialize KDS2010, a Phase 2 oral tablet targeting obesity and neurodegenerative diseases, including Alzheimer's. KDS2010 showed favorable safety and once-daily dosing potential in Phase 1 trials. Scilex will own controlling interest by contributing $50 million of Semnur Pharmaceuticals stock, while IPMC will own 40% for contributing worldwide rights to KDS2010. The global obesity drug market is projected to reach $131 billion by 2028, and the Alzheimer's drug market is expected to exceed $15 billion by 2030.

Diamyd Medical to present new analysis at IDS Congress, showing Diamyd®'s effectiveness in preserving C-peptide and improving glycemic control in Type 1 Diabetes patients with HLA DR3-DQ2, supporting ongoing Phase 3 trial DIAGNODE-3 for potential FDA accelerated approval.

Choosing anti-seizure medications (ASMs) involves considering side effects, seizure types, cost, and physician experience. No single ASM is universally effective; selection depends on individual patient needs. ASMs are categorized as narrow or broad-spectrum, with some seizures resistant to treatment. Generic drugs may differ in effectiveness from brand names. Side effects vary, including weight changes, cognitive issues, and organ impacts. AEDs suppress seizures but do not cure epilepsy. Detailed drug profiles highlight mechanisms, side effects, and dosing strategies.